back

Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C

Subject:

  • Active Substance: Sofosbuvir, Ledipasvir/Sofosbuvir, Simeprevir, Daclatasvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir
  • Name: SOVALDI®, HARVONI®, OLYSIO, DAKLINZA, VIEKIRAX®, EXVIERA®
  • Therapeutic area: Hepatitis C
  • Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA, AbbVie Deutschland GmbH & Co. KG, Janssen-Cilag GmbH, Gilead Sciences GmbH

 

Time table:

  • Publication of final assessment: 17.12.2015

 

Assessment information:

  • Title: Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C
  • Author/Co-Author: KCE (Belgium), AAZ (Croatia), UCSC Gemelli (Italy), HVB (Austria)
  • Dedicated Reviewers: SNHTA (Switzerland), SAGEM HTA (Turkey), ZIN (Netherlands), AETSA (Spain), AIFA (Italy), MoH Slovak Republic (Slovakia), NIPHNO (Norway), HAS (France), MoH Malta (Malta), NVD (Latvia), FIMEA (Finland), SMC (Scotland), IQWiG (Germany), INFARMED (Portugal)

G-BA assessment available for › Sofosbuvir (D-091)› Ledipasvir/Sofosbuvir (D-143)› Simeprevir (D-113)› Daclatasvir (D-129)› Ombitasvir/Paritaprevir/Ritonavir (D-153)› Dasabuvir (D-152)